Search

Author/Creator Osinusi, A.

2. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data. (March 2023)

Authors:
Asselah, T.; Lampertico, P.; Aleman, S.; Bourliere, M.; Streinu-Cercel, A.; Bogomolov, P.; Morozov, V.; Stepanova, T.; Lazar, S.; Suri, V.; Manuilov, D.; Mercier, R.C.; Tseng, S.; Ye, L.; Flaherty, J.F.; Osinusi, A.; Brunetto, M.; Wedemeyer, H.
Journal:
Digestive and liver disease
Issue:
Volume 55(2023)Supplement 1
Page Start:
S74
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis. (March 2023)

Authors:
Lampertico, P.; Aleman, S.; Blank, A.; Bogomolov, P.; Chulanov, V.; Mamonova, N.; Morozov, V.; Sagalova, O.; Stepanova, T.; Suri, V.; Manuilov, D.; Ye, L.; Flaherty, J.F.; Osinusi, A.; Cornberg, M.; Brunetto, M.; Wedemeyer, H.
Journal:
Digestive and liver disease
Issue:
Volume 55(2023)Supplement 1
Page Start:
S73
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir‐containing regimens. Issue 4 (28th December 2017)

Authors:
Bhardwaj, N.; Ragonnet‐Cronin, M.; Murrell, B.; Chodavarapu, K.; Martin, R.; Chang, S.; Miller, M. D.; Feld, J. J.; Sulkowski, M.; Mangia, A.; Wertheim, J. O.; Osinusi, A.; McNally, J.; Brainard, D.; Mo, H.; Svarovskaia, E. S.
Journal:
Journal of viral hepatitis
Issue:
Volume 25:Issue 4(2018)
Page Start:
344
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗